- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04101942
An Internet-delivered Cognitive-behavioral Intervention Provided Soon After Trauma: a RCT
Internet-delivered Prolonged Exposure Provided Soon After Traumic Events: An Efficacy Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE
The primary objective with this study is to investigate the short-term efficacy (primary endpoint at week 3) of Internet-delivered cognitive behavior therapy (ICBT) provided soon after trauma.
SECONDARY OBJECTIVES The secondary objective is to investigate the long-term efficacy (primary endpoint at week 7) of ICBT.
Trial design: Randomized trial where participants are allocated to either ICBT (n=50) or control group (assessment only; n=50). Participants randomized to control group are subsequently offered identical ICBT treatment, so that all participants will eventually receive treatment.
All participants are assessed at baseline (W0), post-treatment (primary endpoint; W3) and at one-month follow-up (secondary endpoint; W7). Long-term follow-up assessments are also conducted at 6- and 12-months. The primary outcome measure is also measured weekly from baseline and up to the 1-month follow-up (W7).
Primary outcome measure used are the Posttraumatic Stress Disorder Checklist for Diagnostic and Statical Manual, Fifth Edition (PCL-5). Secondary outcome measures used are Montgomery Åsberg Depression Rating Scale - Self-report (MADRS-S), Euroqol (EQ-5D) and Trimbos and Institute of Medical Technology Assessment Cost Questionnaire for Psychiatry (TIC-P).
Participants are self-referred through advertisements in newspapers, web-pages, social media and at primary care, psychiatric and emergency clinics throughout Sweden. Interested applicants do an Internet-administered screening on an encrypted webpage using the PCL-5, MADRS-S, Alcohol User Disorders Identification Test (AUDIT), Drug User Disorders Identification Test (DUDIT), TIC-P, questions about inclusion and exclusion criteria and also give general background information. Written information about the study is given including objectives, benefits, risks and requirements imposed by the study.
An assessor calls the participant and conducts a structured clinical interview including The Mini-International Neuropsychiatric Interview (M.I.N.I.). The aim of this interview is to preliminary assess inclusion criteria and rule out exclusion criteria. Information is also given over the phone by the interviewer about the study protocol.
Safety parameters Participants will have the opportunity to report any adverse events during treatment, at posttreatment and follow-up assessment.
Data collection: Data will be collected electronically via the treatment platform.
Main statistical analysis: Between-group estimates on outcome are done using a mixed-effects regression model with repeated measurements. All analyses will be done according to intention to treat and post hoc per protocol analyses will also be conducted.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Stockholm, Sweden
- Karolinska Institutet
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
• Experienced psychological trauma in the past two months according to criterion A for PTSD in the DSM-5 (exposed to death, threatened death, actual or threatened serious injury, or actual or threatened sexual violence).
- At least mild clinical symptoms assessed using the PCL-5
- ≥ 18 years
- Situated in Sweden
- Informed consent
Exclusion Criteria:
- Other serious comorbidity as primary concern (ongoing substance dependence, untreated bipolar disorder, psychotic symptoms, severe depression, borderline personality disorder, high suicidal risk according to the M.I.N.I.)
- Not fluent speaking in Swedish
- Receiving CBT for trauma-related symptoms
- Ongoing trauma-related threat (e.g. living with a violent spouse)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Internet-based CBT
The experimental group will go through active internet-based treatment which is delivered on a safe internet platform.
Treatment is divided into four modules, each containing homework assignments.
Participants in the experimental group will be assigned a therapist that they can contact through a message system in the platform and expect answer within 36 hours on weekdays
|
The experimental group will go through active internet-based treatment which is delivered on a safe internet platform.
Treatment is divided into four modules, each containing homework assignments.
Participants in experimental group will be assigned a therapist that they can contact through a message system in the platform and expect answer within 36 hours.
|
No Intervention: Control condition (assessment only)
Waitlist control, i.e. no active active intervention during waiting list period.
Will be offered treatment after 7 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5)
Time Frame: Baseline, weekly from baseline up to 1-month follow-up, 6 month follow up and 12 month follow up
|
Change in symptoms of post traumatic stress from baseline, during treatment to post treatment and follow up (6 and 12 months).
The PTSD Checklist for DSM-5 (PCL-5) is a 20-item self-report measure that assesses the presence and severity of PTSD symptoms.
All items are scored on a 0-4 scale.
Higher score indicate worse severity.
|
Baseline, weekly from baseline up to 1-month follow-up, 6 month follow up and 12 month follow up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Montgomery Åsberg Depression Rating Scale - Self-report (MADRS-S)
Time Frame: Baseline, post treatment week 3, one-month follow up, 6 month follow up and 12 month follow up
|
Change in depressive symptoms from baseline to post treatment and follow up (1, 6 and 12 months).
The Montgomery Åsberg Depression Rating Scale - Self-report (MADRS-S) is a 9 item self-report measure that assesses the presence and severity of depressive symptoms.
All items are scored on a 0-6 scale.
Higher score indicate worse severity.
|
Baseline, post treatment week 3, one-month follow up, 6 month follow up and 12 month follow up
|
Euroqol, EQ-5D
Time Frame: Baseline, post treatment week 3, one-month follow up, 6 month follow up and 12 month follow up
|
Change in overall health from baseline to post treatment and follow up (1, 6 and 12 months).
EQ-5D is a standardised self-report measure of overall health status measured in terms of five dimensions; mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Mobility dimension asks about the person's walking ability.
Self-care dimension asks about the ability to wash or dress by oneself, and usual activities dimension measures performance in "work, study, housework, family or leisure activities".
In pain/discomfort dimension, it asks how much pain or discomfort they have, and in anxiety/depression dimension, it asks how anxious or depressed they are.
The respondents self-rate their level of severity for each dimension using a three-level scale: 1 having no problems, 2 having some problems and 3 having extreme problems.
A higher score indicate worse severity.
|
Baseline, post treatment week 3, one-month follow up, 6 month follow up and 12 month follow up
|
Trimbos and Institute of Medical Technology Assessment Cost Questionnaire for Psychiatry (TIC-P)
Time Frame: Baseline, post treatment week 3, one-month follow up, 6 month follow up and 12 month follow up
|
Change in economic costs from baseline, post treatment, 1 month, 6 month and 12 months follow up.
TIC-P collect data on medical consumption and productivity losses in patients with mild to moderate mental health problems.
A higher score indicate worse severity.
|
Baseline, post treatment week 3, one-month follow up, 6 month follow up and 12 month follow up
|
Adverse Events
Time Frame: Baseline, post treatment week 3, one-month follow up, 6 month follow up and 12 month follow up
|
Number of adverse events from baseline, 1 month, 6 month and 12 months follow up.
|
Baseline, post treatment week 3, one-month follow up, 6 month follow up and 12 month follow up
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Erik Andersson, PhD, Karolinska Institutet
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EPN
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Post Traumatic Stress Disorder
-
University of California, Los AngelesDefense Advanced Research Projects Agency; Defense Group, Inc.CompletedPost-traumatic Stress Disorder | Post-Traumatic Stress Disorder, ChronicUnited States
-
Weill Medical College of Cornell UniversityCompletedPost-traumatic Stress Disorder | Complex Post-Traumatic Stress DisorderUnited States
-
University of California, Los AngelesRecruitingPost-traumatic Stress Disorder | Post-Traumatic Stress Disorder in ChildrenUnited States
-
University of UtahEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedPost-Traumatic Stress Disorder in Children | Post-Traumatic Stress Disorder in AdolescenceUnited States
-
University of ZurichCompletedPost Traumatic Stress Disorder (PTSD) | Complex Post-Traumatic Stress Disorder (CPTSD)Switzerland
-
University of NottinghamNottinghamshire Healthcare NHS Trust; Lincolnshire Partnership NHS Foundation...CompletedDomestic Violence | Trauma, Psychological | Post-Traumatic Stress Disorder in Children | Narrative Exposure Therapy | Post-Traumatic Stress Disorder in Adolescence | Post-Traumatic Stress Disorder ComplexUnited Kingdom
-
Praxis Precision MedicinesTerminatedStress Disorders, Post-Traumatic | Trauma and Stressor Related Disorders | Post Traumatic Stress Disorder | Stress Disorder | Post-traumatic Stress Disorder | Mental DisorderUnited States
-
Erkin Oğuz SARINot yet recruitingPost-Traumatic Stress DisorderTurkey
-
University Hospital, LilleNot yet recruiting
-
Steinn SteingrimssonRecruiting
Clinical Trials on Internet-based CBT
-
Stockholm UniversityNot yet recruitingInsomnia | Sleep Disturbance | Autism Spectrum DisorderSweden
-
Karolinska InstitutetCompletedBurnout Syndrome | Adjustment Disorder
-
Uppsala UniversityCompletedDepression | Myocardial Infarction | AnxietySweden
-
Karolinska InstitutetCompletedAnxiety DisordersSweden
-
Karolinska InstitutetCompleted
-
Per TornvallUppsala University; Mid Sweden UniversityRecruiting
-
Center for Psychological ConsultationNational Institute of Mental Health (NIMH)CompletedPTSD | Obsessive Compulsive Disorder | Anxiety DisordersUnited States
-
Seattle Children's HospitalMayo Clinic; National Institute of Diabetes and Digestive and Kidney Diseases... and other collaboratorsCompletedPancreatitis, Chronic | Pancreatitis, Acute RecurrentUnited States
-
Karolinska InstitutetRegion StockholmCompleted
-
Uppsala UniversityCompletedDepression | Cancer | AnxietySweden